

Evan J. Vickers proposes the following substitute bill:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**Medication Amendments**  
2025 GENERAL SESSION  
STATE OF UTAH  
**Chief Sponsor: Evan J. Vickers**  
House Sponsor:

---

---

**LONG TITLE**

**General Description:**

This bill addresses participation in a federal drug discount program.

**Highlighted Provisions:**

This bill:

- defines terms;
- prohibits a pharmaceutical manufacturer from restricting, prohibiting, or otherwise interfering with a 340B entity's ability to:
  - acquire a 340B drug; or
  - participate in the 340B drug discount program;
- permits the Public Employees' Benefit and Insurance Program to adjust its business practices to mitigate any resulting financial impacts; and
- requires the commissioner of insurance to designate a third party entity to:
  - receive certain deidentified claim information;
  - confirm whether a 340B entity participates in the drug discount program; and
  - report the claim information to a pharmaceutical manufacturer.

**Money Appropriated in this Bill:**

None

**Other Special Clauses:**

None

**Utah Code Sections Affected:**

ENACTS:

**31A-46-311**, Utah Code Annotated 1953

**31A-46-312**, Utah Code Annotated 1953

---

---

*Be it enacted by the Legislature of the state of Utah:*

29 Section 1. Section **31A-46-311** is enacted to read:

30 **31A-46-311 . Prohibited actions with respect to the 340B drug discount program.**

31 (1) As used in this section,"manufacturer" means a pharmaceutical manufacturer, including  
32 an agent or affiliate of a pharmaceutical manufacturer.

33 (2) A manufacturer may not:

34 (a) directly or indirectly restrict or prohibit:

35 (i) a pharmacy from contracting with a 340B entity, including by denying the  
36 pharmacy access to a drug that is manufactured by the manufacturer;

37 (ii) a 340B entity from contracting with a pharmacy, including by denying the 340B  
38 entity access to a drug that is manufactured by the manufacturer;

39 (iii) the acquisition, dispensing, or delivery of a 340B drug to any location authorized  
40 by a 340B entity to receive the drug, unless prohibited by federal law; or

41 (iv) a 340B entity from receiving 340B drug discount program pricing for a 340B  
42 drug, including by imposing a time limitation on a 340B entity to replenish or  
43 submit a claim for a 340B drug;

44 (b) directly or indirectly:

45 (i) require a 340B entity to purchase a 340B drug from a supplier if the manufacturer  
46 would otherwise permit the 340B entity to purchase a drug that is not a 340B drug  
47 from the supplier; or

48 (ii) require a 340B entity to submit any claim data, utilization data, or information  
49 about a 340B entity's contracts with a third-party as a condition for allowing the  
50 acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity, unless  
51 the data or information sharing is required by federal law; or

52 (c) interfere with:

53 (i) a contract between a pharmacy and a 340B entity; or

54 (ii) the ability of a pharmacy and a 340B entity to enter into a contract.

55 (3) The Public Employees' Benefit and Insurance Program created in Section 49-20-103  
56 may adjust the program's business practices to mitigate any financial impacts resulting  
57 from this section.

58 (4) Nothing in this section is to be construed to conflict with federal law.

59 Section 2. Section **31A-46-312** is enacted to read:

60 **31A-46-312 . Designated entity -- Claim information sharing and use -- 340B**  
61 **entity public reporting.**

62 (1) As used in this section:

- 63 (a) "Board of pharmacy" means the Utah State Board of Pharmacy created in Section  
64 58-17B-201.
- 65 (b) "Claim information" means information related to a claim for a 340B drug that is:  
66 (i) dispensed by a contract pharmacy; and  
67 (ii) manufactured by a single manufacturer.
- 68 (c) "Contract pharmacy" means a pharmacy contracting with an entity participating in  
69 the 340B drug discount program to dispense drugs purchased through the 340B drug  
70 discount program.
- 71 (d) "Designated entity" means a third party entity that is designated as described in  
72 Subsection (2).
- 73 (e) "Participating 340B entity" means a 340B entity that is a hospital described in 42  
74 U.S.C. Sec. 256b(a)(4)(L).
- 75 (2)(a) The commissioner, in collaboration with the board of pharmacy, shall designate  
76 one third party entity to receive claim information as described in Subsection (3).
- 77 (b) In making the designation described in Subsection (2)(a), the commissioner shall  
78 ensure that the third party entity:  
79 (i) is capable of carrying out the requirements of this section;  
80 (ii)(A) is not owned or controlled by a pharmaceutical manufacturer; and  
81 (B) does not otherwise have a contractual or other relationship with a  
82 pharmaceutical manufacturer that would create a conflict of interest; and  
83 (iii) in carrying out the provisions of this section, will use:  
84 (A) technology that complies with privacy and security requirements under state  
85 and federal law; and  
86 (B) reasonable and necessary terms.
- 87 (c) If the commissioner is unable to designate a third party entity that meets the  
88 requirements of Subsection (2)(b), a participating 340B entity is not required to post  
89 as described in Subsection (6).
- 90 (3) A participating 340B entity shall:  
91 (a) provide to the designated entity the following claim information:  
92 (i) prescription number;  
93 (ii) prescribed date;  
94 (iii) fill date;  
95 (iv) national drug code;  
96 (v) quantity;

- 97           (vi) pharmacy identification; and  
98           (vii) 340B covered entity identification;  
99        (b) ensure the claim information provided is deidentified in accordance with federal law;  
100        and  
101        (c) provide the claim information in accordance with the rules described in Subsection  
102        (7).
- 103 (4) Upon request, the designated entity:  
104        (a) shall inform a pharmaceutical manufacturer whether a 340B entity is a participating  
105        340B entity that provides claim information for any 340B drug; and  
106        (b) may provide to a pharmaceutical manufacturer claim information for a 340B drug  
107        manufactured by the pharmaceutical manufacturer that the designated entity received  
108        under Subsection (3).
- 109 (5)(a) The designated entity or a pharmaceutical manufacturer may only use claim  
110        information received under this section to identify a rebate for an insurer or a third  
111        party administrator that is ineligible for payment under the pharmaceutical  
112        manufacturers policy.  
113        (b) The designated entity or a pharmaceutical manufacturer may not use claim  
114        information received under this section to:  
115        (i) establish restrictions or limitations on a participating 340B entity's ability to  
116        purchase a 340B drug, including by establishing:  
117            (A) allocations on purchasing based on the number of claims for which the  
118            participating 340B entity provides claim information; or  
119            (B) time limits for a participating 340B entity to replenish or replace inventory of  
120            a 340B drug;  
121        (ii) recoup from a participating 340B entity a discount for a 340B drug;  
122        (iii) discriminate against, lower the reimbursement for, or impose any separate  
123        condition on a participating 340B entity; or  
124        (iv) take any other action that is not expressly authorized under this part.
- 125 (6) A participating 340B entity shall post on the participating 340B entity's publicly  
126        available website:  
127        (a) the name of the participating 340B entity;  
128        (b) a copy of the participating 340B entity's annual 340B program recertification;  
129        (c) if the participating 340B entity is required to conduct a community health needs  
130        assessment under Section 501(r)(3)(A), Internal Revenue Code, a copy of the

- 131 participating 340B entity's community health needs assessment;
- 132 (d) a statement that the participating 340B entity is in compliance with the 340B drug
- 133 discount program; and
- 134 (e) a description of the impact of the 340B drug discount program on the patients and
- 135 community served by the participating 340B entity.
- 136 (7) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the
- 137 commissioner, in collaboration with the board of pharmacy, shall make rules that
- 138 establish the frequency in which a participating 340B entity shall provide claim
- 139 information to the designated entity.

140 Section 3. **Effective Date.**

141 This bill takes effect on May 7, 2025.